Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Bristol Myers Squibb Co.

Share:
Related BMY
Fast Money Picks For June 30
The Note Moving Pharma Giants Today
Exelixis-Roche's Skin Cancer Drug's FDA Review Delayed - Analyst Blog (Zacks)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Bristol Myers Squibb Co. (NYSE: BMY), and slightly raised its price target from $38.00 to $39.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Bristol Myers Squibb Co. closed on Tuesday at $34.22.

Latest Ratings for BMY

DateFirmActionFromTo
Jun 2015Piper JaffrayInitiates Coverage onUnderperform
May 2015BerenbergInitiates Coverage onHold
Apr 2015Deutsche BankMaintainsHold

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

Around the Web, We're Loving...

Get Benzinga's Newsletters